# Kriya Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kriya-therapeutics

- Industry: Biotechnology
- Headquarters: Palo Alto, US
- Website: www.kriyatherapeutics.com
- Total disclosed funding: $860M
- Latest round: Series D (Jul 31, 2025)
- Investors on record: 16

## About

Founded in 2019 and based in California, US, Kriya Therapeutics, Inc. operates as a biotechnology company that focuses on the treatment of diabetes and obesity. The company was co-founded by Shankar Ramaswamy (CEO), Roger Jeffs (Vice-Chairman), and Dr. Fraser Wright (Chief Scientific Advisor). In July 2025, Kriya Therapeutics, Inc. raised USD 313.30 million in series D funding co-led by new investor Premji Invest and returning investor Patient Square Capital, with participation from other returning investors Narya and JDRF T1D Fund. In September 2025, Kriya Therapeutics, Inc. raised USD 7.52 million in series D funding from unspecified investors. The funding was part of a larger USD 320.82 million series D round. The company aims to design, develop, and manufacture gene therapies. Kriya is built on two distinct technology platforms: its computationally enabled proprietary platform for rational vector design (SIRVE) and its manufacturing platform for production (STRIPE). The company is advancing a deep and diversified pipeline of innovative gene therapies spanning rare and prevalent diseases in multiple therapeutic verticals, with current pipeline programs addressing metabolic, ophthalmic, and oncologic diseases. The company will use the funding to support product development, expand its team, and grow its customer base.

## Funding rounds

- Series D, Jul 31, 2025, $313M — Premji Invest, JDRF T1D Fund, Narya, Patient Square Capital
- Series C, Jul 27, 2023, $91M — Patient Square Capital
- Series C, May 10, 2022, $270M — Foresite Capital, CAM Capital, QVT funds, Alumni Ventures Group, Dexcel Pharma Technologies Ltd., JDRF T1D Fund, Narya, Transhuman Capital, BlueBird Ventures, Patient Square Capital, Lightswitch Capital
- Series B, Jun 30, 2021, $100M — Foresite Capital, CAM Capital, QVT funds, Alumni Ventures Group, Dexcel Pharma Technologies Ltd., JDRF T1D Fund, Amplo, Woodline Partners, Narya, Transhuman Capital, BlueBird Ventures, Patient Square Capital, Hongkou Capital
- Series A, May 4, 2020, $86M — Asia Alpha Private Equity, Foresite Capital, QVT funds, Dexcel Pharma Technologies Ltd., Amplo, Narya, Transhuman Capital, BlueBird Ventures
- Seed, Oct 1, 2019 — Transhuman Capital

## Investors

- Transhuman Capital (https://capitalatlas.ai/funds/transhuman-capital) — Seed, Series A, Series B, Series C
- Asia Alpha Private Equity (https://capitalatlas.ai/funds/asia-alpha-private-equity) — Series A
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series A, Series B, Series C
- QVT funds — Series A, Series B, Series C
- Dexcel Pharma Technologies Ltd. — Series A, Series B, Series C
- Amplo (https://capitalatlas.ai/funds/amplo) — Series A, Series B
- Narya (https://capitalatlas.ai/funds/narya) — Series A, Series B, Series C, Series D
- BlueBird Ventures (https://capitalatlas.ai/funds/bluebird-ventures) — Series A, Series B, Series C
- CAM Capital — Series B, Series C
- Alumni Ventures Group (https://capitalatlas.ai/funds/alumni-ventures-group) — Series B, Series C
- JDRF T1D Fund (https://capitalatlas.ai/funds/jdrf-t1d-fund) — Series B, Series C, Series D
- Woodline Partners — Series B
- Patient Square Capital (https://capitalatlas.ai/funds/patient-square-capital) — Series B, Series C, Series D
- Hongkou Capital — Series B
- Lightswitch Capital (https://capitalatlas.ai/funds/lightswitch-capital) — Series C
- Premji Invest — Series D